Steven A. Vasilev, M.D., MBA, FACOG, FACS, FACN, ABIHM, ABOIM
Dr. Steven A. Vasilev is a gynecologic oncology specialist who is currently affiliated with Cedars-Sinai Marina del Rey Hospital. He is one of the few surgeons who specialize in the treatment of gynecologic malignancies, including ovarian, uterine, and cervical cancer, by using advanced minimally invasive and robotic surgery. Furthermore, the medical expert performs surgery on complex benign problems such as suspicious pelvic uterine and ovarian masses and excision of recurrent advanced endometriosis. Dr. Steven A. Vasilev's practice philosophy is to uniquely combine state-of-the-art surgical technology with integrative healing. He is Principal Investigator with the National Institutes of Health at the moment. The medical specialist has nearly 40 years of professional experience, over which he has achieved extraordinary breakthroughs in his field of practice. Dr. Steven A. Vasilev has been recognized as a surgical innovator, minimally invasive surgery pioneer, and thought leader. Until now, he has authored over 90 publications, abstracts, and book chapters.
The renowned medical specialist received his degree from USC Keck School of Medicine and completed his residency and fellowship at the Los Angeles County Hospital and USC Keck School of Medicine. Dr. Steven A. Vasilev is quadruple board certified in gynecology, gynecologic oncology, integrative health, and holistic medicine. He is a member of the Society of Gynecologic Oncologists and the Academy of Integrative Health and Medicine. The medical expert has served as faculty and professor at UCLA, USC, UCI, and Loma Linda School of Medicine, and the City of Hope. Dr. Steven A. Vasilev is also a member of the Alpha Omega Alpha Medical Honor Society and has been selected by Best Doctors for 16 years in a row, between 2001 and 2017. This places him in the top 5% of specialists in his field. Dr. Steven A. Vasilev has published numerous peer-reviewed studies and he is the author of a surgical textbook and a book on science-based holistic integrative gynecologic cancer treatment. In 2014, he was recognized as a Fellow of the American College of Nutrition. The medical expert was also a Public Educator and Speaker with the American Cancer Society.
Education & Training
USC Keck School of Medicine
LAC - USC Medical Center
LAC - USC Medical Center
USC Keck School of Medicine
USC Norris Cancer Center
Memberships & Affiliations
Publications & Media
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Morgan, R. J., Doroshow, J. H., Leong, L., Schriber, J., Shibata, S., Forman, S., Hamasaki, V., Margolin, K., Somlo, G., Alvarnas, J., McNamara, M., Longmate, J., Raschko, J., Chow, W., Vasilev, S., McGonigle, K., Yen, Y.
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
Morgan, R. J., Speyer, J., Doroshow, J. H., Margolin, K., Raschko, J., Sorich, J., Akman, S., Leong, L., Somlo, G., Vasilev, S.
calene lymph node sampling in cervical carcinoma: a reappraisal.
Vasilev, S. A., Schlaerth, J. B.
Basic fibroblast growth factor in retardation of doxorubicin extravasation injury.
Vasilev, S. A., Morrow, C., Morrow, C. P.
Ability of visual tests to predict underlying cervical neoplasia. Colposcopy and speculoscopy.
Lonky, N. M., Mann, W. J., Massad, L. S., Mutch, D. G., Blanco, J. S., Vasilev, S. A., Finan, M. A., Scotti, R. J.
Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy.
McGonigle, K. F., Shaw, S. L., Vasilev, S. A., Odom-Maryon, T., Roy, S., Simpson, J. F.
Ovarian histopathology in breast cancer patients receiving tamoxifen.
McGonigle, K. F., Vasilev, S. A., Odom-Maryon, T., Simpson, J. F.
Intestinal peritoneal sling as an adjunct to radical pelvic operation and pelvic irradiation.
Vasilev, S. A., McGonigle, K. F., Spencer-Smith, E. L.
Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.
Morgan, R. J., Synold, T. W., Gandara, D., Muggia, F., Scudder, S., Reed, E., Margolin, K., Raschko, J., Leong, L., Shibata, S., Tetef, M., Vasilev, S., McGonigle, K., Longmate, J., Yen, Y., Chow, W., Somlo, G., Carroll, M., Doroshow, J. H.
Comparison of the polymerase chain reaction and Southern blot analysis in detecting and typing human papilloma virus deoxyribonucleic acid in tumors of the lower female genital tract.
Monk, B. J., Cook, N., Ahn, C., Vasilev, S. A., Berman, M. L., Wilczynski, S. P.
Prognostic significance of human papillomavirus DNA in vulvar carcinoma.
Monk, B. J., Burger, R. A., Lin, F., Parham, G., Vasilev, S. A., Wilczynski, S. P.
Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer.
Burger, R. A., Monk, B. J., Kurosaki, T., Anton-Culver, H., Vasilev, S. A., Berman, M. L., Wilczynski, S. P.
Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis.
Chan, J. K., Zhang, M., Kaleb, V., Loizzi, V., Benjamin, J., Vasilev, S., Osann, K., Disaia, P. J.
Cervical cancer with paraaortic metastases: significance of residual paraaortic disease after surgical staging.
Kim, P. Y., Monk, B. J., Chabra, S., Burger, R. A., Vasilev, S. A., Manetta, A., DiSaia, P. J., Berman, M. L.
Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan, R. J., Newman, E. M., Doroshow, J. H., McGonigle, K., Margolin, K., Raschko, J., Chow, W., Somlo, G., Leong, L., Tetef, M., Shibata, S., Hamasaki, V., Carroll, M., Vasilev, S., Akman, S., Coluzzi, P., Wagman, L., Longmate, J., Paz, B., Yen, Y., Klevecz, R.